Mesalazine
Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. It is generally used for mildly to moderately severe disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly-effective.
Clinical data | |
---|---|
Trade names | Asacol, Lialda, Pentasa, others |
Other names | mesalamine, 5-aminosalicylic acid, 5-ASA, Mesalamine (USAN US) |
AHFS/Drugs.com | Monograph |
MedlinePlus | a688021 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, rectal |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | orally: 20–30% absorbed rectally: 10–35% |
Metabolism | Rapidly & extensively metabolized intestinal mucosal wall and the liver |
Elimination half-life | 5 hours after initial dose. At steady state 7 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.001.745 |
Chemical and physical data | |
Formula | C7H7NO3 |
Molar mass | 153.137 g·mol−1 |
3D model (JSmol) | |
Melting point | 283 °C (541 °F) |
| |
| |
(verify) |
Common side-effects include headache, nausea, abdominal pain, and fever. Serious side-effects may include pericarditis, liver problems, and kidney problems. Use in pregnancy and breastfeeding appears safe. In people with a sulfa allergy certain formulations may result in problems. Mesalazine is an aminosalicylate and anti-inflammatory. It works by direct contact with the intestines.
Mesalazine was approved for medical use in the United States in 1987. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2021, it was the 239th most commonly prescribed medication in the United States, with more than 1 million prescriptions.